

Covalon Successfully Cultures Cells Using Its Collagen-Based Scaffold For Tissue Regeneration

MISSISSAUGA, ONTARIO--(CCNMatthews - April 21, 2005) - Covalon Technologies Ltd. (TSX VENTURE:COV) has successfully cultured cells on its collagen-based scaffold. Covalon will now proceed to the next phase of research and development on the scaffold for tissue regeneration.

Collagen and gelatin are biological materials that are used extensively in the medical field. Once prepared, using Covalon's proprietary technologies, they form a matrix (scaffold) that is biocompatible and biodegradable. The materials are useful as wound dressings, as supports for tissue regeneration, and the delivery of drugs.

"The successful growth of animal cells on Covalon's proprietary cellular scaffold demonstrates that the matrix is well accepted by cells. The cells adhere and grow very well on the matrix," stated Frank DiCosmo, Covalon's CEO.

Covalon Technologies Ltd. is a company that has developed and patented advanced therapeutic biomaterials for wound care and surgical applications and coatings. Covalon has developed collagen-based wound care products for reducing the incidence of Hospital -Acquired Infections (HAI) for wounds using the collagen scaffold. Polymer chemistry and surface coating technology have been combined to create a range of time-release drug delivery platforms that are applied to many medical devices to treat many critical conditions. A variety of applications for these technologies have been identified and specific products have been developed. The products offer features and benefits providing solutions to many of the problems caused by current devices and their material properties that are used by most medical device manufacturers and suppliers.

This document contains forward-looking statements. These statements relate to future events or future performance. In some cases, forward-looking statements can be identified by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential", "continue", or the negative of any of these terms or comparable terminology. Such statements reflect the current views of management of the Company with respect to future events. Actual events or results may differ materially. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. The TSX Venture Exchange has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved of the contents of this release.

For further information please contact: William Jackson
Chief Financial Officer
Covalon Technologies Ltd.
T: (905) 568-8400
F: (905) 568-5200
www.covalon.com

office@covalon.com
www.covalon.com

